论文部分内容阅读
B 细胞性慢性淋巴细胞白血病(B-CLL)是白血病/淋巴瘤中最常见的类型之一,其预后差异很大,细胞毒药物的使用通常只限于进展期病人或伴有大的淋巴瘤和/或脾肿大等合并症病人。然而这些病人的一个主要问题是复杂的免疫缺陷,造成对感染和继发恶性肿瘤的敏感性增加,因而细胞毒药物要慎重使用。干扰素在抗肿瘤的同时刺激免疫机理,既往用干扰素治疗 CLL 无效,是由于治疗的对象均为晚期患者,而此次作者研究对象为早期 CLL 病人。
B-cell chronic lymphocytic leukemia (B-CLL) is one of the most common types of leukemia / lymphoma and has a very different prognosis. The use of cytotoxic drugs is usually restricted to advanced patients or to patients with large lymphoma and / Or splenomegaly and other complications of patients. However, one of the major problems with these patients is the complex immunodeficiency that leads to increased susceptibility to infection and secondary malignancies, so cytotoxic drugs should be used with caution. Interferon in the anti-tumor while stimulating the immune mechanism, the previous treatment of CLL with interferon ineffective, because the treatment of patients are advanced patients, and the authors of this study for the early CLL patients.